KARD — Kardigan, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2123613 ·
Last close
$13.19
Market Cap
$1.23B
52W High
$27.00
52W Low
$12.23
ADV30
527,058
Next earnings
2026-11-12
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -86,604,000 -58,568,000 649,251,000 78,889,000 76,733,000
Jun 2026 0 — -75,232,000 -116,236,000 721,786,000 384,005,000 106,264,000
Mar 2026 0 — -58,710,000 -56,071,000 348,190,000 81,548,000 648,816,000
Dec 2025 — — — — 390,942,000 108,989,000 641,277,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-160,102,000
Investing CF
$-61,455,000
Financing CF
$537,419,000
CapEx
$-7,502,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.72
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-453,396,000
Inventory
—
Receivables
—
ST Investments
$213,590,000
EBIT TTM
$-217,145,000
Pretax Income TTM
$-251,938,000
Interest Exp TTM
—
Analysts
8

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -201,836,000 -191,941,000 390,942,000 641,277,000 -250,335,000 -151,056,000
Dec 2024 0 -96,656,000 -88,658,000 63,526,000 146,720,000 -83,194,000 -18,825,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$721,786,000
Forward EPS
$-4.17

Peers — same industry

TickerNameMarket CapLastDaily %
SLN Silence Therapeutics plc $1.23B $19.80 —
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —
AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL $1.23B $13.14 —
AVLN Avalyn Pharma Inc. $1.24B $27.92 —
NKTR NEKTAR THERAPEUTICS $1.23B $35.91 —

News headlines (Yahoo Finance, 1h cache)

Kardigan: Q3 Earnings Snapshot
2026-11-12 12:21 · Yahoo
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
2026-11-12 12:00 · Yahoo
Kardigan to Participate in the Jefferies Global Healthcare Conference
2026-11-11 12:00 · Yahoo
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
2026-11-07 16:14 · Yahoo
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
2026-11-06 21:05 · Yahoo
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
2026-09-30 12:00 · Yahoo
Kardigan to Present at Two September Investor Conferences
2026-09-02 20:05 · Yahoo
3 Top Founder Led Stocks To Watch With Up To 82% Revenue Growth
2026-10-25 03:15 · Yahoo
Kardigan And 2 Founder Run Stocks To Own
2026-10-20 15:15 · Yahoo
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
2026-08-11 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.